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Processes in the development of atherosclerotic lesions can lead to plaque rupture or erosion, 
which can in turn elicit myocardial infarction or ischaemic stroke. The aims of this study were 
to determine whether Toll-like receptor 7 (TLR7) gene expression levels influence patient 
outcome and to explore the mechanisms linked to TLR7 expression in atherosclerosis.  
Methods and results 
Atherosclerotic plaques were removed by carotid endarterectomy (CEA) and subjected to gene 
array expression analysis (n=123). Increased levels of TLR7 transcript in the plaques were 
associated with better outcome in a follow-up study over a maximum of 8 years. Patients with 
higher TLR7 transcript levels had a lower risk of experiencing major cardiovascular and 
cerebrovascular events (MACCE) during the follow-up period after CEA (hazard ratio: 2.38, 
p=0.012, 95% CI 1.21-4.67). TLR7 was expressed in all plaques by T cells, macrophages and 
endothelial cells in capillaries, as shown by immunohistochemistry. In short-term tissue 
cultures, ex vivo treatment of plaques with the TLR7 ligand imiquimod elicited dose-dependent 
secretion of IL-10, TNF-α, GM-CSF, and IL-12/IL-23p40. This secretion was blocked with a 
TLR7 inhibitor. Immunofluorescent tissue analysis after TLR7 stimulation showed IL-10 
expression in T cells, macrophages and vascular smooth muscle cells. TLR7 mRNA levels in 
the plaques were correlated with IL-10 receptor (r=0.4031, p<0.0001) and GM-CSF receptor A 
(r=0.4354, p<0.0001) transcripts. 
Conclusion 
These findings demonstrate that TLR7 is abundantly expressed in human atherosclerotic 
plaques. TLR7 ligation elicits the secretion of pro-inflammatory and anti-inflammatory 
cytokines, and high TLR7 expression in plaques is associated with better patient outcome, 










suggesting that TLR7 is a potential therapeutic target for prevention of complications of 
atherosclerosis. 
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Atherosclerosis is the major cause of myocardial infarction and stroke. Atherosclerotic lesions 
have complex structures and show extensive infiltration by immune cells, such as macrophages 
and T cells.1 Inflammatory components have been implicated in plaque rupture2, which can lead 
to myocardial infarction or stroke.  
Many inflammatory mediators, such as innate and adaptive cytokines, chemokines, and 
receptors, have significant functions in atherosclerosis.3 Toll-Like Receptors (TLRs) were 
originally found to recognize conserved motifs in pathogens, called pathogen-associated 
molecular patterns (PAMPs), such as the lipopolysaccharides that are secreted by bacteria. 
Recently, TLRs have also been reported to recognize endogenous host molecules that are 
released during cell death and injury, referred to as damage-associated molecular patterns 
(DAMPs). 4 
Currently, several TLRs in humans have been identified; some localize to the cell surface, 
whereas others are found intracellularly and span endosomal membranes.4, 5 Initial studies on 
TLR function in atherosclerosis have demonstrated that TLR4 activation in mouse models 
increases the progression of the disease and a genetic variant in humans heightens the CVD 
risk. 5  Recent studies have shown that TLR2 activation leads to endothelial erosion and 
increases the risk of thrombotic complications.6 However, Salagianni et al have recently 
reported that TLR7 protects against atherosclerosis in experimental models of the disease.7 
A better molecular understanding of the late stages of atherosclerosis is paramount for 
improving several aspects of disease management, including its diagnosis and prevention. The 
prospective BiKE (Biobank of Karolinska Carotid Endarterectomies) project was initiated to 
examine the molecular mechanisms underlying the formation of atherosclerotic plaques.8, 9 
Patients scheduled for carotid endarterectomy (CEA) on Karolinska Hospital were 










consecutively enrolled and transcript profiles of the removed plaques were analysed. Transcript 
profile analysis is a sensitive method of detecting and mapping ongoing processes in plaques. 
In a previous study, we have examined whether transcript signatures from the removed plaques 
correlated with subsequent events in the patients. Our study demonstrated, as a proof of concept, 
that the inclusion of gene expression profiles of the carotid plaques that are collected during 
endarterectomy improves the prediction of adverse events, compared with the use of only the 
classical risk markers in patients with atherosclerosis.10  
We set up an analysis with the aim of linking specific transcripts in atherosclerotic lesions to 
patient outcome. One candidate of interest has been identified: TLR7.7 In this study we found 
and validated that high TLR7 levels correlate with better patient outcome in cases of severe 
atherosclerosis. We also conducted a thorough protein-level investigation of the processes 















MATERIALS AND METHODS 
Sample collection 
Materials from the Biobank of Karolinska carotid Endarterectomies (BiKE) project were 
obtained after all participants had provided informed written consent, per the Declaration of 
Helsinki and the Karolinska Institute ethics committee. The study included a total of 179 
atherosclerotic plaque tissue samples from patients who underwent CEA at Karolinska 
University Hospital, Stockholm, Sweden. The patient characteristics are summarized in Table 
1. The majority of the patients underwent standard endarterectomy under sedation and local 
anaesthesia. After being rinsed, the plaque was frozen instantly on dry ice for subsequent 
isolation of RNA. For immunohistochemical or immunofluorescent analysis plaque was 
paraffin-imbedded for morphological analysis. 
RNA isolation 
Total RNA was isolated using an RNeasy Mini kit followed by DNase treatment according to 
the manufacturer’s instructions. RNA quality was analysed on an Agilent 2100 Bioanalyzer, 
and RNA concentration was measured with a NanoDrop spectrophotometer. Low-
concentration and low-quality samples were omitted. 
Follow-up and definitions of events 
The BiKE database 8-10 was merged with the Swedish Hospital Discharge Register and the 
Swedish Cause of Death Register for the follow-up of adverse cardiovascular, cerebrovascular, 
and vascular events. Major adverse cardio- and cerebrovascular events (MACCE) were defined 
as the combined incidence of myocardial infarction, stroke, percutaneous coronary intervention, 
coronary artery bypass grafting, endovascular intervention of peripheral arteries and open 
surgery on peripheral arteries, as reported to the registers listed above. Ischaemic events were 










defined as fatal or nonfatal myocardial infarction or ischaemic stroke. The retrieval of 
myocardial infarction and stroke incidence data from the Swedish Hospital Discharge Register 
and the Swedish Cause of Death Register is a reliable, validated alternative to the use of revised 
hospital discharge and death certificates.11, 12 Total number of MACCE and MI events in the 
microarray discovery cohort was 34 and 24 respectively. In the qPCR validation cohort 47 
MACCE and 33 MI events occurred. 
Gene expression microarrays 
RNA samples were hybridized and scanned at the Karolinska Institute Affymetrix core facility 
using Affymetrix HG-U133 plus 2.0 arrays. The resulting cel files were preprocessed by RMA 
normalization13, as implemented in the Affymetrix Power Tools 1.10.2 apt-probeset-summarize 
package. Further information is described in a previous study.10 The number of samples for 
which both microarray measurements and MACCE information was available was 123. 
Real-time PCR 
Total RNA was reverse-transcribed with SuperScript II reverse transcriptase and random 
hexamers, using a master mix for all samples in 1 batch. The same amount of total RNA was 
used for each sample, based on measurements from a NanoDrop 1000 spectrophotometer. 
TaqMan probes and primers for TLR7 were purchased as assay-on-demand products. PCR was 
conducted in 4 96-well plates on a 7700 HT fast real-time PCR system. All samples were 
measured in duplicate. All real-time PCR analyses were performed using the 2-ΔCt method, with 
the mean of all samples used as a calibrator.  
Immunohistochemistry  
Serial paraffin sections of human CEA specimens were incubated with primary antibodies to 
CD3 (pre-diluted), CD8 (1:50), CD163 (pre-diluted), CD68 (1:50) and TLR7 (1:600) overnight 










at 4°C. Signals were detected with biotinylated secondary antibodies and developed with 
Vulcan Fast Red. 
Immunofluorescence  
Sections were incubated for 1 h in RT with primary antibodies against CD3 (1:500), CD8 
(1:50), CD163 (pre-diluted), CD68 (1:50), FoxP3 (1:200), α-actin (1:400). CD31 (1:50) and 
von Willebrand factor (1:2000) and overnight at 4°C with antibodies to TLR7 (1:600), IL-10 
(1:3000) and CD69 (1:50). Sections were blocked with 5% serum and incubated with the 
following secondary antibodies: Dylight 488 anti-mouse. Dylight 594 anti-rabbit (1:300), and 
Alexa 647 anti-goat (1:200). Autofluorescence was blocked with 0.03% Sudan Black, and 
DAPI was used for nuclear staining. Sections were analysed with a Leica TCS-SP5 confocal 
microscope. No differences in staining patterns were observed between consecutive single-, 
double-, or triple-stained sections. 
For IL-10 staining, carotid plaque tissue (n=1) was separated in 4 large pieces. Half of the pieces 
were stimulated ex-vivo with 12.5 µg/ml IMQ, the unstimulated pieces where used for control. 
Pieces were collected after 1.5 h and 8 h. Pieces were fixed in 4% zinc-formaldehyde solution 
and embedded in paraffin after dehydration.  
Ex vivo human carotid plaque stimulation with TLR7 agonist  
For cytokine release assay: Twelve fresh carotid plaques were obtained from patients 
undergoing CEA. At the operation day the plaque was cut into small pieces (~2 mm3), and 
distributed into the wells of a 48-well plate and thereafter pre-incubated for 1 h in RPMI 1640 
medium supplemented with 10% human serum at 37°C in 5% CO2 before stimulattion with 
TLR7 agonist imiquimod (IMQ). The following concentrations were used in a dose response 
challenge 2.5, 5, or 12.5 µg/ml IMQ. Each dose was run in duplicates and the reported values 
are the average for each concentration. See Supplemental Materials: Reagents for information 










about IMQ. As control 100 ng/ml lipopolysaccharide (LPS) was used to assure live cells present 
in the tissue after the mincing. After 20 h of stimulation, supernatants from the plaques were 
collected and stored at -80°C for cytokine analysis. Supernatant from unstimulated tissue was 
used as control. See figure 5. 
Analysis of cytokine secretion 
Cytokine levels in supernatants were measured after ex vivo stimulation using MesoScale 
technology (MSD). IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13, and TNF-α were 
measured with the “Proinflammatory 10-plex panel 1”, and GM-CSF, IL-1α, IL-5, IL-7, IL-
12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, and VEGF were measured with a “Cytokine 10-
plex panel 1” (MSD) according to the manufacturer’s protocol. For IL-8, a separate ELISA kit 
was used. For the cytokine measurements after ex vivo IMQ stimulation of isolated CD4, CD8 
and CD14 cells, single cytokine  ELISA kits were used for IL-10, TNF-α and GM-CSF. 
In vitro blocking assay of TLR7 
In separate inhibition experiments eight carotid plaques were used. The minced plaque tissue 
was pre-incubated for 1 h with 5 µM of a TLR7 inhibitor (ODN 20958) before addition of TLR7 
agonist IMQ (12.5 µg/ml). For the cytokine measurements after ex vivo TLR7 inhibition and 
ELISA kits were used for IL-10, TNF-α, GM-CSF and IL-8.  See figure 6. 
Reagents 
All reagents are listed in the supplemental file. 
Statistical analysis  
Statistical analysis was performed using R 3.1.2 (R Foundation, Tables 1 and 2 and Figure 1). 
Survival was analysed using a Cox regression model and implemented in the survival 
bioconductor package (version 2.37.7), as described previously.10, 14 Baseline data in table 1 are 










presented as median [first quartile, third quartile]. In the survival analysis (figure 1), subjects 
accrued follow-up time from time of CEA until the time of event (MACCE or ischaemic event, 
depending on the analysis) or censoring, whichever came first. MACCEs and MIs were 
classified with the ICD-10 codes as described previously.15 TLR7 expression values were 
categorized into tertiles. Cox proportional hazards models were used to estimate hazard ratios 
(HRs) and 95% confidence intervals (CIs) for the lowest tertile of TLR7 expression versus the 
middle and highest tertiles combined. Cox models were further adjusted for age, sex, and LDL-
cholesterol (Table 2). The proportional hazard assumption was tested by means of Schoenfeld’s 
residuals. No evidence of departure from this assumption was observed. Kaplan-Meier plots 
were generated using the plot function in the survival package (2.37.7). 
The size of the qPCR validation cohort was fixed, but we used the power SurvEpi R-package 
to calculate that there was 0.76 power to detect the same association that was found in the 
microarray cohort. Primary data for this calculation was input using the measurements from the 
microarray cohort. The number of samples that had both qPCR measurements and MACCE 
information was 133. Fifty-six samples from the qPCR measurements were independent of the 
microarray dataset. 
Mean cytokine secretion (± SD) by TLR7 stimulation with different levels of imiquimod (0, 
2.5, 5, 12.5 µg/ml) are presented in Figure 5 and Table S2. Fixed-effects linear regression was 
used to test for a linear trend between imiquimod stimulation and mean cytokine secretion 
(Table S2) performed with Stata release 14.1 (StataCorp, College Station, TX).  Inhibition 
experiments were analysed by one-way paired ANOVA (Figure 6). Graphs and inhibition 
analysis were performed using Prism (GraphPad Software Inc. version 6.0). Bonferroni 
correction for multiple testing was used when appropriate. P-values < 0.05 were considered 
statistically significant.  











TLR7 transcript levels in carotid plaques correlate with patient outcome 
Transcript profiles of the gene expression data from carotid plaques (n=123) were analysed in 
samples from the BiKE biobank to determine whether TLR7 levels in plaques correlated with 
future events and patient outcome. Follow-up data from the clinical registries were extracted 
for patients who had undergone CEA (Table 1). Patients were followed for median 1410 days 
/ 46 months / 3.8 years with a maximum of 100 months (8.3 years), depending on when they 
entered the study.  
Transcript profiles and outcome were compared for patients who experienced major adverse 
cardio- and cerebrovascular events (MACCE) or ischaemic event (Figure 1, Table 2), and our 
analysis implicated TLR7 as a strong candidate. Comparing outcome for patients, based on 
tertile levels of the TLR7 transcript in their plaques, patients in the lowest tertile had a higher 
risk of encountering a MACCE during the follow-up period after carotid CEA (black line in the 
Kaplan-Meier plot, Figure 1). Baseline clinical data levels did not differ among the patients in 
the different tertiles of TLR7 transcript levels (Table 1). The Cox regression hazard ratio for 
MACCEs (2.38, p=0.012) was not significantly affected by the inclusion of age, sex, and LDL 
level as risk factors (Table 2). Our analysis show that high TLR7 levels correlate to fewer 
cardio- and cerebrovascular events. 
To verify these results, real-time RT-PCR was performed on an increased number of carotid 
plaques (n=133), which demonstrated similar results (HR 1.91, p=0.027); fewer MACCEs 
developed over time in patients with higher TLR7 transcript levels (Figure 1b). 
TLR7+ cells in human atherosclerotic plaques 
Next, we measured TLR7 levels by immunohistochemistry. TLR7 was expressed in all plaques 
(Figure 2a, b, e, and f). The staining pattern indicated that TLR7 was expressed primarily on 










cells of haematopoietic origin. Consecutive sections that were stained with T cell (Figure 2a, 
b) and macrophage (Figure 2c, d) markers showed that TLR7 co-localized with the areas that 
were infiltrated by these cell types.  
To identify the specific cell types that expressed TLR7, we performed double and triple staining 
using a panel of surface markers analysed by confocal immunofluorescence microscopy. For 
macrophages, we used CD68 for the M1 subtype (Figure 3a, b) and CD163 for the M2 subtype 
(Figure 3c, d). Both macrophage types expressed TLR7. However, several TLR7+ cells in the 
sections were negative for both markers, indicating that other cell types also expressed TLR7.  
TLR7 is differentially expressed between artery-lining endothelium and capillary vessels 
Various endothelial cell subtypes differentially expressed TLR7. In the endothelium that lined 
the carotid lumen, we did not detect any TLR7+ endothelial cells. TLR7+ cells were detected 
below the endothelium (von Willebrand factor-positive) in clearly separate cells (Figure 3e, f). 
However, in the capillary vessels of certain patients, TLR7 co-stained with von Willebrand 
factor (Figure 3g, h) in a ring-like pattern typical of capillaries. Signals for -actin, a marker 
of vascular smooth muscle cells, did not overlap with TLR7 (data not shown). Analysis of 
medium sized normal arteries (iliaca) indicated that TLR7 expression is not present in lumen 
endothelium and, only occasionally faintly in the capillaries (figure S1). 
Robust TLR7 expression in T cells infiltrating atherosclerotic plaques 
We hypothesized that T cells constitute a significant TLR7+ cell population and identified them 
by co-staining for CD3 and CD8 (Figure 4a-d). CD3+CD8- cells were assumed to be CD4+ T 
cells (Figure 4c, d), although CD4 was not detected by direct staining. CD4 and CD8 cells were 
observed in the plaques, often in clusters. CD8+ and CD8- T cells stained robustly for TLR7.  
CD69 staining was used to investigate the activation state of the infiltrating T cells. Clusters of 
activated T cells expressed CD69 and TLR7 (Figure 4e-h). Some regulatory CD4 T cells were 










observed in the plaques, based on FoxP3 expression (Figure 4j-l), and were also positive for 
TLR7. 
Plaques produced cytokines ex vivo in response toTLR7 ligand 
To determine the effects of TLR7 activation in plaques, we developed an ex vivo stimulation 
protocol for plaque tissue. Fresh carotid plaques were cut into small pieces before being treated 
with the TLR7-specific ligand imiquimod (Figure 5). To verify that plaque cells remained 
capable of responding to stimuli under the incubation conditions, the plaque tissue was also 
treated with the TLR4 ligand LPS (data not shown). After incubation with these ligands, the 
medium was collected and analysed by multiplex ELISA for 20 cytokines (see Materials and 
Methods).  
Notably, the plaque tissue responded to TLR7 ligation by producing IL-10 in a dose-dependent 
manner. There was also a dose-dependent increase in TNF-, GM-CSF, and IL-12/IL-23p70 
after administration of imiquimod (Figure 5). Several cytokines were unaffected by TLR7 
stimulation, including IL-2, IL-4, IL-5, IL-6, IL-7, IL-13, and IFN, despite the substantial 
secretion of these cytokines by plaque tissue regardless of whether ligand was added (Table 
S2). The concentrations of certain cytokines were low or close to the limit of detection, such as 
IL-1 and IL-17 (Table S2). 
Inhibition of TLR7 reduces the cytokine secretion  
To further investigate the specificity of TLR7 activation, an inhibition step was introduced. The 
ex vivo protocol for the stimulation of fresh carotid plaque (see above) was repeated with the 
inclusion of an incubation with a TLR7 inhibitor (see Materials and Methods). This resulted in 
a strongly reduced release of cytokines (Figure 6). The inhibition was pronounced for IL-10, 
TNF- and GM-CSF. Inhibitor only did not affect the cytokine release (data not shown). 
Comparing different TLR7 ligands 










Imiquimod has been used in other studies because it is a TLR7 specific ligand. We sought to 
investigate the activation level for imiquimod in comparison with other TLR7 ligands. The in 
vitro system of TLR7-transformed HEK cells was used, and two other ligands, CL307 and 
R848, were also tested. The comparisons showed a more moderate response to imiquimod than 
to CL307 and R848 (Figure S2). 
IL-10 secretion in plaques and in vitro. 
To trace the cellular origin of the IL-10 secretion within the plaque tissue, two approaches were 
used: an ex vivo protocol with carotid plaques and an in vitro protocol using PBMCs from 
patients. First, fresh carotid plaque tissue was incubated with imiquimod for 1.5 or 8 hours and, 
thereafter, fixed and embedded for immunofluorescent analysis. IL-10 was detected in a portion 
of both CD163+ macrophages and T cells after the short incubation with the TLR7 ligand, 
indicating a fast response to stimulation (Figure 7). Another pattern was detected for SMCs, in 
which IL-10-positive SMCs were detected both in the control samples (untreated tissue) and 
after incubation with the TLR7 ligand, indicating a basal level of IL-10 production independent 
of ligand (Figure 7). 
In the second approach, PBMCs from patients were used to set up primary cell cultures of T 
cells and macrophages. The response to TLR7 ligand in purified leucocyte populations was 
very low, indicating a clear difference with the complex plaque tissue. Stimulation with the 
TLR7 ligand showed hardly any induction of cytokines in the CD4+ T cells. Regarding CD8 
cells there was a tendency in decreased cytokine release after the TLR7 ligand was added to 
culture. After challenging the macrophages with the TLR7 ligand, a tendency of increased 
amount of secreted IL-10 was detected (Figure S3). Neither the response from T cells nor 
macrophages were statistically significant. 
TLR7 transcript levels correlate with cytokine receptor mRNA 










To determine whether TLR7 levels correlated with cytokines or their corresponding receptors 
in plaques, we extracted the data from our transcript profiles for the cytokine transcripts that 
were secreted in a dose-dependent manner after TLR7 stimulation. TLR7 levels correlated with 
cytokine receptors, such as IL-10 receptor (r=0,416, p<0.0001) and GM-CSFRA (r=0.4354, 
p<0.0001) (see Table S3). 











Large-scale analysis of expression in affected tissue has the potential to identify specific 
molecular pathological processes as well as to demonstrate the activity of gene products and 
their links to downstream proteins. Such studies can increase understanding of the individual 
differences in a diseased population.  
Our biobank project, BiKE, has allowed us to extract data from a gene array expression 
screening of carotid plaques. We sought to identify individual genes that influence outcome in 
atherosclerotic patients. By using a bioinformatics analysis, in which we correlated 
transcriptome data from carotid plaques to follow-up data and patient outcome, we linked TLR7 
to a better prognosis and the occurrence of fewer ischaemic events. The follow-up data were 
collected over 8 years. However, this study was not powered to completely exclude complex 
dependence with other known risk factors. A larger study is needed for that. 
Initially, it was surprising that a TLR family member was linked to protective mechanisms in 
patients, given the previous findings that TLR activation is detrimental in atherosclerosis.5 
Nevertheless, 2 exceptions have been reported: endosomal TLR3 and TLR7 have been shown 
to be atheroprotective in experimental mouse models.5, 7 Additionally, recent publications from 
other groups have reported TLR7-dependent anti-inflammatory control mechanisms.16, 17 
TLR7 was expressed in all analysed plaques. In our screening of markers for cells that are 
usually found in the plaque and in healthy intima, we noted a co-expression of TLR7 in 
infiltrating leukocytes but not in smooth muscle cells or the luminal endothelium. Using 
immunofluorescence analysis, TLR7 was detected in macrophages and T cells. Recent studies 
have identified subtypes of T cells and macrophages that do not necessarily drive pathogenesis 
but may mediate healing, likely by primarily eliciting anti-inflammatory responses.18, 19  










Regarding the downstream effects of TLR7 activation, two recent studies have implicated 
TLR7 in the control or abatement of inflammation and in the adaptive immune response in both 
macrophages16 and T cells17, cell types which are frequently found in atherosclerotic lesions. 
In an experimental study of airway inflammation, imiquimod promoted the resolution of 
inflammation by inducing the lipid mediator resolvin D in murine macrophages16, an effect that 
has also been observed in vitro in human monocytes. Furthermore, TLR7 induces anergy in 
CD4+ T cells in HIV-positive patients.17. A similar mechanism might exist in atherosclerotic 
tissue. In contrast to the effects in HIV-positive patients, the effects of this response would be 
favourable to individuals with heart disease. Whether the same immunosuppressive 
mechanisms are present in human CD8 T cells is unknown. 
Endothelial cells showed differential TLR7 expression in the plaque. No co-expression was 
found in the endothelium that lines the carotid lumen. However, TLR7 co-stained with von 
Willebrand factor in capillary vessels. Thus, whether there is general TLR7 activation during 
new vessel formation or whether this pattern is an atherosclerosis-specific process remains to 
be determined. 
To examine how plaque tissue responds to TLR7 activation, we developed an ex vivo model 
using plaque immediately after CEA. After stimulation with the synthetic ligand imiquimod ex 
vivo, several cytokines such as IL-10, showed a dose-dependent response, whereas some 
cytokines were unchanged. IL-10 is an immune-suppressing cytokine that has been suggested 
to ameliorate atherosclerosis.20, 21 These findings indicate that TLR7 signalling supports an anti-
inflammatory response in atherosclerotic plaques through IL-10. 
Conversely, imiquimod induced the dose-dependent secretion of pro-inflammatory cytokines, 
such as TNF-. The function of GM-CSF in plaques is under debate. We noted a TLR7 ligand-
dependent GM-CSF response. A recent study has demonstrated that GM-CSF functions as a 











growth factor and increases macrophage apoptosis in advanced lesions.22 These effects are 
mediated by IL-23, another cytokine that we detected after TLR7 activation. Several prominent 
pro-inflammatory cytokines were unaffected by the TLR7 ligand in the plaques, including IFN 
and IL-6.  
Our ex vivo data suggested that TLR7 activation modulates and fine-tunes the balance between 
the induction and suppression of inflammation. Although the response to endogenous TLR7 
ligands in plaques is unknown, we hypothesize that this equilibrium is tilted in favour of an 
inflammation-resolving pathway. The first TLR7 specific ligands to be identified were viral, 
single-stranded RNA, but several mammalian endogenous ligands have recently been 
identified, such as RNA from apoptotic cells, miRNA and extracellular RNA from necrotic 
cells23. In atherogenesis, RNA from apoptotic and necrotic cells and from tissue damage could 
be a plausible source of ligands. 
We were interested in determining whether the immunosuppressive response originates from T 
cells or macrophages. Clusters of CD8+ and CD4+ cells exist in the plaques. FoxP3+ CD4 cells 
constitute a Treg population that is atheroprotective, particularly in experimental settings. 
Recent data have suggested that there are CD8+ T cells with an immunosuppressive capacity24 
and that such CD8+ Tregs influence atherosclerosis.24. To shed light on these mechanisms, 
PBMCs from patients undergoing CEA were used for in vitro analysis. However, the in vitro 
system with purified CD4 T cells, CD8 T cells or macrophages did not at all mount the same 
strong response in IL-10 secretion as that observed in the plaque tissues examined in the ex vivo 
protocols. It therefore seems possible that the specific interactions of the cells in the plaques 
prime the response and that the milieu to elicit fast TLR7 response is enhanced in plaques. Our 
tissue analysis with confocal immunofluorescence analysis detected IL-10 in T cells and 
macrophages in the plaques after a short incubation with a TLR7 ligand, which perhaps 
triggered the activation of the surrounding cells. Together, our data suggest that upon TLR7 










activation, T cells and CD163 macrophages in the plaque quickly respond with a boost of IL-
10 that is propagated through the tissue and elicits a greater release of IL-10 from VSMCs. This 
can occur without extra stimulation by a synthetic ligand because IL-10-positive smooth muscle 
cells are present in human lesions, as has also been previously shown by others.20  
However, there are some limitations to our study. Our cohort of patients is relatively small, 
especially when it comes to the material that has undergone transcript analysis. The analysis of 
TLR7 transcript levels and the correlation to patients’ outcome was not powered to completely 
exclude complex dependence with other known risk factors, a larger study is needed for that. 
We also note that the statistical significance has some variation between our two technical 
approaches (eg gene array profiling versus real-time PCR) to collect transcript data. Therefore 
further validation of the data will shed light in these questions. 
In conclusion, we have identified TLR7 as one marker of better outcome in patients with severe 
atherosclerosis. In patients who undergo CEA, increased levels of the TLR7 transcript in the 
removed plaque is associated with fewer adverse cardiovascular events. TLR7 is expressed in 
T cells and macrophages within the plaque and in capillary endothelial cells. When plaque 
tissue is challenged with the TLR7 ligand imiquimod ex vivo, IL-10 is secreted, one of the major 
anti-inflammatory cytokines, as well as the proinflammatory mediator TNF-. Collectively, 
these data implicate that TLR7 may be part in modulating inflammatory responses in 
atherosclerosis by counteracting effect of proinflammatory cytokines. 
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Table 1. Baseline characteristics-  
 Microarray qPCR 
 TLR7-low TLR7-medium TLR7-high P TLR7-low TLR7-medium TLR7-high P 
n 44 44 45  41 40 42  
Male, % (n) 78.6 (33) 81.8 (36) 75.6 (34) 0.37 82.9 (34) 60 (24) 87.8 (36) 0.78 
Age (years)  73 [68.2, 76] 74 [66.5, 78] 71 [65, 77] 0.36 72 [66, 77] 70 [64.5, 76.2] 70 [64, 78] 0.82 
Body mass index (kg/m2) 26 [23.7, 27.5] 25 [23.4, 27.9] 25 [23.1, 26.8] 0.8 25 [22.6, 27.7] 27 [24.5, 28.6] 26 [24.2, 28.7] 0.58 
Smoking % (n) 69.4 (25) 57.5 (23) 52.4 (22) 0.52 52.9 (18) 54.1 (20) 55 (22) 0.5 
Stenosis %  80 [73.8, 80] 80 [75, 80] 80 [78.8, 80] 0.34 80 [77.5, 80] 80 [80, 80] 80 [77.5, 80] 0.46 
Total cholesterol (mmol/L) 4.2 [3.8, 5.4] 4.6 [3.9, 5.4] 4.6 [4.1, 5.3] 0.56 4.2 [3.6, 5.1] 4.3 [4, 5.4] 4.6 [3.77, 5.32] 0.5 
LDL (mmol/L) 2.5 [2.3, 3.65] 2.7 [2.08, 3.5] 2.4 [2.18, 3] 0.18 2.2 [1.9, 2.77] 2.3 [1.9, 3.05] 2.4 [1.87, 3.23] 0.37 
Statins % (n) 87.5 (35) 70.5 (31) 84.4 (38) 0.96 82.5 (33) 82.5 (33) 85 (34) 0.7 
Antihypertensives % (n) 81.8 (36) 68.2 (30) 93.3 (42) 0.07 78 (32) 87.5 (35) 90.5 (38) 0.17 











Antiplatelet agents % (n) 85 (34) 93.2 (41) 93.3 (42) 0.63 95.1 (39) 90 (36) 95.1 (39) 0.94 
Symptomatic % (n) 76.2 (32) 81.8 (36) 73.3 (33) 0.97 61 (25) 77.5 (31) 70.7 (29) 0.48 
Diabetes % (n) 22.7 (10) 25 (11) 26.7 (12) 0.56 24.4 (10) 32.5 (13) 19.5 (8) 0.35 
hsCRP (mg/L) 2.1 [0.94, 6.2] 2.5 [1.2, 6.9] 3.2 [1.3, 7] 0.59 2.9 [1.6, 5.6] 2.7 [1, 4.9] 2.2 [1.2, 7.6] 0.95 
 
Baseline data for microarray and qPCR cohorts categorized on the basis of tertiles of TLR7 expression. Categorical data are reported as percentages (count), and 
numerical data are expressed as median [Q1, Q3]. P-values were calculated using a linear regression model on the numerical value of the TLR7 expression. The 
term symptomatic refers to if the patients have had a transient ischemic attack, amaurosis fugax or minor ischemic stroke before the carotid artery surgery.  hsCRP 
stands for high sensitive CRP, LDL for Low-density lipoprotein cholesterol. 
 












Table 2. Relationship between gene expression levels in carotid artery plaques of TLR7 and 
outcome.  















1.91 (P=0.027)  
CI 1.08-3.4 
2.28 (P=0.044)  
CI 1.02-5.09 
1.67 (P=0.145)    
CI 0.84-3.31 




1.91 (P=0.027)  
CI 1.08-3.39 
2.10 (P=0.072)    
CI 0.936-4.69 
1.63 (P=0.163)    
CI 0.82-3.24 




1.87 (P=0.033)    
CI 1.05-3.32 
2.24 (P=0.049)  
CI 1-5.02 
1.63 (P=0.162)      
CI 0.82-3.25 




1.90 (P=0.028)    
CI 1.07-3.38 
2.20 (P=0.057)    
CI 0.978-4.93 
1.65 (P=0.155)      
CI 0.83-3.28 
TLR7, adj. for 
age and sex 
2.18 (P=0.024) 
CI 1.11-4.30 
1.82 (P=0.042)   
CI 1.02-3.23 
2.07 (P=0.076)  
CI 0.93-4.63 
1.57 (P=0.199)  
CI 0.79-3.13  
TLR7, adj. for 




1.80 (P=0.045)    
CI 1.01-3.21 
2.02 (P=0.090)    
CI 0.90-4.56 
1.55 (P=0.214)  
CI 0.78-3.09 
Hazard ratio (HR) (95% confidence interval, P-values) from Cox regression models for the 
lowest tertile of TLR7 expression versus the middle and highest combined.  











Figure 1.Worse outcome were found for patients with lower levels of TLR 7 transcript in 
their plaques. Kaplan-Meier curve illustrating MACCE-free survival of patients with TLR7 
expression of highest tertile (black), the middle tertile (dark grey) and the lowest tertile (light 
grey). A) Microarray cohort with 34 MACCE and 24 ischaemic event. B) qPCR cohort with 47 
MACCE and 33 ischaemic events. Below each plot, the count of event-free patients is indicated. 
The x-axis scale of the study was time since CEA in months. Hazard ratio (HR) for the lowest 
tertile of TLR7 expression versus the middle and highest tertiles combined from a Cox 
regression is reported in the upper-right corner. 
Figure 2. Immunohistochemical staining of carotid plaques for TLR7 and cell markers. 
(a, b) TLR7 staining in a T cell-rich area. (c) CD3-positive staining in consecutive slides. (d) 
CD8 staining in consecutive slides. (e, f) TLR7. (g) CD68. (h) CD163. Positive cells are stained 
with Vulcan fast red, and the nuclei are stained blue. Scale bars: (a, f) 100 µm. (b-d, f-g) 10 
µm. 
Figure 3. Co-localization of TLR7 with macrophage and endothelial cell markers in 
human carotid lesions detected by immunofluorescence staining. (a, b) TLR7 (red) co-
localization with the macrophage marker CD68 (green). (c, d) Co-expression of TLR7 with the 
macrophage marker CD163 (green). Differential expression of TLR7 in endothelial cells. (e, f) 
No co-expression of TLR7 with lumen endothelial cells (vWF, green). (g, h) Co-localization of 
TLR7 with capillary endothelial cells (vWF, green). Nuclei are stained blue. Scale bars: (a-f) 
7.5 µm, (g-h) 25 µm. 
Figure 4. Co-localization of TLR7 and T cell markers in lesions detected by 
immunofluorescence staining. (a-d) TLR7 (red) is co-expressed in CD4+ and CD8+ (green) 
cells. CD4 T cells are labelled with arrows (CD3+ CD8-). (e-h) CD3 (grey), CD69 (green) and 










triple staining of CD3+, TLR7 and the T cell activation marker CD69. (i-l) CD3+ cells, FoxP3 
cells (green) and triple staining of TLR7, CD3, and FoxP3. Nuclei are stained blue. Scale bars: 
7.5 µm.  
Figure 5. Ex vivo dose–dependent cytokine secretion in human carotid plaques after TLR7 
stimulation. Fresh plaques were used at the same day of operation. Minced plaque tissue was 
incubated in vitro with increasing concentration of TLR7 ligand imiquimod. IL-10, GM-CSF, 
TNF-α and IL-12/IL-3p40 secretion significantly increased in a dose-dependent manner after 
20 h of stimulation with 2.5, 5, and 12.5 µg IMQ, measured by multiplex ELISA of total 20 
cytokines. For each cytokine, fixed-effects linear regression was used to test for a linear trend 
between IMQ stimulation and mean cytokine secretion. P-values were adjusted for multiple 
comparisons of 20 cytokines using Bonferroni correction. Number of plaques analysed n=12. 
Summary of all cytokine data in table S2. 
Figure 6. Reduction of cytokine secretion in human carotid plaques after inhibition of 
TLR7. Fresh plaques were used at the same day of operation. Minced plaque tissue was 
incubated in vitro with optimal concentration of TLR7 ligand in presence or absence of TLR7 
inhibitor. IL-10, GM-CSF, TNF-α secretion was strongly decreased after the addition of 5 µM 
TLR7 inhibitor (ODN 20958) and 12.5 µg/ml IMQ. Number of plaques analysed n=8.  Data 
presented as mean ± SD. For each cytokine one-way paired ANOVA followed by Bonferroni 
post hoc tests was used to compare the different groups. 
Figure 7. Co-localization of IL-10 with macrophage, T cell and smooth muscle cell 
markers after ex vivo stimulation with IMQ. Localization of IL-10 secreting cells after ex-
vivo short term stimulation of plaque tissue with TLR7 ligand.  a) IL-10 (red) and the M2 
macrophage marker CD163 (green). b) IL-10 (red) co-expression with CD3 (green). c) IL-10 
(red) co-localization with a-actin (green). Nuclei are stained blue. Scale bars: 10 µm. 
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